小剂量氟哌噻吨美利曲辛辅助治疗腹泻型肠易激综合征临床疗效观察

目的 应用抗抑郁药氟哌噻吨/美利曲辛(黛力新)辅助治疗腹泻型肠易激综合征患者,观察其对患者的肠道功能紊乱改善的疗效.方法 136例临床诊断为腹泻型肠易激综合征患者,随机分为两组(各68例),治疗组(匹维溴胺、双歧三联活菌、黛力新口服),对照组(匹维溴胺、双歧三联活菌口服),疗程均为12周.治疗前行腹泻、腹胀和腹痛等肠道功能紊乱症状评估,治疗12周后按疗效观察标准分析,分别观察两组症状持续改善、临床疗效及不良反应发生情况.结果 12周末治疗组腹痛减轻、腹泻症状改善均高于对照组,分别为98.2%vs 80.8%、94.1%vs 82.4%(P＜0.05或＜0.01).治疗组有效率高于对照组,92.6%vs 76.5%(P＜0.01).两组不良反应总发生率11.8%vs7.4%(P＞0.05).结论 抗抑郁药黛力新联用匹维溴胺、双歧三联活菌能明显改善腹泻型肠易激综合征肠道功能紊乱症状,是肠易激综合征辅助治疗的一种有效安全方法.

Study on therapeutic effect of low dose Deanxit in treatment of diarrhea-predominant irritable bowel syndrome

Objective To observe the therapeutic effect and safety of low dose antidepressant Deanxit in combination with bifid-triple viable and pinaverium bromide on the gastrointestinal symptoms in patients who suffered from diarrhea-predominant irritable bowel syndrome（D-IBS）.Methods All of 136 D-IBS patients were divided into two groups randomly,each group containing 68 cases（treatment group：Deanxit,pinaverium bromide and bifid-triple viable;control group：pinaverium bromide and bifid-triple viable）.The treatment course lasted for 12 weeks,the therapeutic effect and adverse reactions were observed after finishing the treatment course.Results After treatment of 12 weeks,the effective rate of abdominal pain and diarrhea in treatment group were significantly higher than those in control group,respectively 98.2% vs 80.8%,94.1% vs 82.4%（P0.05 or 0.01）.The total effective rate of treatment group was significantly higher than that of control group,92.6% vs 76.5%（P0.01）.No obvious side-effects were found in both groups,there was no significant difference of side-effects between the treatment group and the control group 11.8% vs 7.4%（P0.05）.Conclusion Low-dose Deanxit combined with pinaverium bromide and bifid-triple viable is safe and effective in treatment of D-IBS patients.